Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

Kim Kyung-Ah, CEO of Samsung Bioepis, stated in her New Year's address on the 2nd, 'The U.S. launch of biosimilar drugs, ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

INR:1526. win fortune slots EU approves dolutegravir dispersible tablets for the treatment of pediatric patients aged ≥ 4 weeks and ≥ 3 kg Biogen acquires r ...

INR:1994. top casino in world How to build a medical insurance policy that adapts to the development of primary medical care? The National Medical Insurance A ...